Lenalidomid Medical Valley (Lenalidomide)

Lenalidomide is used in hematologic malignancies that rely on abnormal plasma‑cell or lymphoid proliferation.

• Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: contributes to disease control when combined with other agents in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to modulation of cytokine production, inhibition of angiogenesis, and direct anti‑proliferative and pro‑apoptotic effects on malignant cells, while enhancing immune‑mediated tumor clearance.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may be mild to moderate.
• Constipation: reduced bowel movements causing discomfort.
• Rash: mild skin eruptions or itching.
• Neutropenia: lowered neutrophil count increasing infection risk.
• Thrombocytopenia: reduced platelet count leading to easy bruising.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophils requiring medical intervention.
• Severe rash or Stevens‑Johnson syndrome: extensive skin involvement.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Second primary malignancies: emergence of new cancers during therapy.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns.

• Pregnancy: contraindicated (Category X); ensure effective contraception for both patient and male partners.
• Thrombosis risk: assess history of clotting disorders and consider prophylactic anticoagulation when appropriate.
• Renal impairment: evaluate kidney function; dose adjustments may be required.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias early.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure.
• Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, direct oral anticoagulants): may heighten bleeding risk.
• P‑glycoprotein inhibitors (e.g., cyclosporine): can increase plasma concentrations.
• Nephrotoxic agents (e.g., aminoglycosides): may exacerbate renal impairment.
• Immunosuppressants (e.g., corticosteroids): may augment immunomodulatory effects.